Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has formed a consortium to develop thermostable technology to advance RiVax(TM) and other rapidly acting vaccines. Soligenix received a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to support this work. [More]

The newly discovered Th22 cells are a previously unknown subset of T helper cells. T helper cells are white blood cells that help activate other immune cells when the body is infected by viruses or bacteria. At the same time they help the body to tolerate own tissue and to prevent or curb inflammation. [More]

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development. [More]

New discoveries about anti-HIV antibodies may bring researchers a step closer to creating an effective HIV vaccine, according to a new paper co-authored by scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. [More]

Scientists at Johns Hopkins and their colleagues have developed sugar-coated polymer strands that selectively kill off cells involved in triggering aggressive allergy and asthma attacks. Their advance is a significant step toward crafting pharmaceuticals to fight these often life-endangering conditions in a new way. [More]

At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). [More]

At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). [More]

Research and Markets (http://www.researchandmarkets.com/research/d3e55b/pediatric_board_re) has announced the addition of the "Pediatric Board Review" report to their offering. [More]

Researchers at the University of Alabama at Birmingham (UAB) have uncovered the genetic identity of a cellular receptor for the immune system's first-response antibody, a discovery that sheds new light on infection control and immune disorders. The discovery is such a crucial part of immunology that UAB researchers, in conjunction with Japanese researchers, are asking that the gene linked to this antibody receptor be renamed to better describe its role in early immune responses. [More]

As flu season got underway this fall, Dr. Catherine Monteleone, an allergist, noticed that her office started to receive an unusually high number of calls from people with egg allergy. They previously had avoided flu vaccines because of their sensitivity to eggs. This year, with all the attention being paid to the novel H1N1 influenza, those patients want to be protected against flu, and they contacted her to find out if they are candidates for inoculation. [More]

Though tuberculosis "is one of the world's leading killers … few citizens, scientists and policymakers are demanding more attention to TB research, treatment and prevention. … It's time to bring TB research into the 21st century," Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, writes in an MSNBC opinion piece. [More]

The growing asthma & allergy friendly(TM) Certification Program announced today that it has developed and adopted a certification standard and testing protocol for Non-Disinfecting Hard Surface Spray Cleaning Products. The asthma & allergy friendly(TM) Certification Program - administered by the Asthma and Allergy Foundation of America (AAFA) in partnership with the international research organization, Allergy Standards Limited (ASL) - is an independent, non-exclusive certification program created to scientifically test and identify consumer products that are more suitable for people with asthma and allergies. [More]

Researchers at the La Jolla Institute for Allergy & Immunology have found that previous influenza infections may provide at least some level of immunity to the H1N1 "swine" flu. "The question we asked was, "Is the swine flu more like the seasonal flu or like a totally new strain of influenza where there would be no immunity?," said Alessandro Sette, Ph.D., an internationally recognized vaccine expert and director of the La Jolla Institute's Center for Infectious Disease. [More]

The American Cancer Society and ENT and Allergy Associates, LLP (ENTA) are once again teaming up to bring a strong and relevant anti-smoking message to teens and ENTA patients through a strategic partnership that includes outreach to local high schools and patient education. [More]

A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time this week in the Journal of Clinical Investigation. [More]